BioCryst Pharmaceuticals BCRX Payments for Restructuring
Payments for Restructuring at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRestructuring.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's payments for restructuring.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's payments for restructuring?
- BioCryst Pharmaceuticals (BCRX) reported payments for restructuring of $5.72M in Q1 2026.
- How has BioCryst Pharmaceuticals's payments for restructuring changed year-over-year?
- BioCryst Pharmaceuticals's payments for restructuring increased by 2635.9% year-over-year, from $209K to $5.72M.
- What does payments for restructuring mean?
- Reflects the actual cash outflows associated with organizational restructuring initiatives, including severance packages, facility closures, or contract terminations. Monitoring these payments helps investors assess the cash impact of strategic pivots or operational streamlining efforts.